`

Argos Therapeutics, Inc. (NASDAQ: ARGS)

Specialities :
Dendritic cells;hiv;renal cancer
revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$1.5M
size-icon Size
51 - 200

Frequently Asked Questions About Argos Therapeutics, Inc. (NASDAQ: ARGS)

What does Argos therapeutics, inc. (nasdaq: args) do?+

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform. Argos most advanced product candidate, rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, rocapuldencel-T is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis-based product candidate, AGS-004, for the treatment of human immunodeficiency...

What are Argos therapeutics, inc. (nasdaq: args)'s specialties? +

Dendritic cells;hiv;renal cancer

What is Argos therapeutics, inc. (nasdaq: args)'s revenue? +

Argos therapeutics, inc. (nasdaq: args)'s revenue is 11m - 100m

What is Argos therapeutics, inc. (nasdaq: args)'s company size? +

Argos therapeutics, inc. (nasdaq: args) has 51 - 200 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.